Huluwa Pharmaceutical Group Honored with Hainan Provincial Science and Technology Progress Award

Haikou, November 15, 2022 – At the Hainan Provincial Science and Technology Awards Conference, Huluwa Pharmaceutical Group was honored with the Second Prize of the Hainan Provincial Science and Technology Progress Award 2021 for its research project titled “Process Optimization of Xiao Er Fei Re Ke Chuan Granules and Its Application Research”. The project was led by a team of key contributors, including Liu Jingping, Liu Quanguo, Hu Junbin, Li Peihu, Liu Ping, Wang Jia, Chen Keling, and He Yanbo.

Under the leadership of Chairman Liu Jingping, Huluwa Pharmaceutical Group conducted systematic research on process optimization and application of Xiao Er Fei Re Ke Chuan Granules, encompassing manufacturing process optimization, specification improvement, pharmacological studies, and clinical validation. As a result of these efforts, the upgraded Huluwa Xiao Er Fei Re Ke Chuan Granules (exclusive 4 g/bag in China) was approved for marketing in November 2015, featuring improved specification, higher safety and efficacy, and better taste. This product is the only one of its kind in China to have undergone comprehensive specification upgrades, including quantitative analysis of forsythin, precise control of baicalin content (15 mg/bag), dual-limit control of total ephedrine alkaloids (0.48-3.6 mg/bag). ensuring both safety and clinical efficacy. These advancements deliver enhanced safety profile, optimized clinical efficacy, and superior therapeutic outcomes for recurrent cough in children. As a result, the preparation method of Xiao Er Fei Re Ke Chuan Granules was recognized with the 21st China Patent Excellence Award (2019) (Patent Application No.: ZL201010134951). This patented technology also contributed to the product winning the Second Prize in the 2021 Hainan Provincial Science and Technology Progress Award. Prior to this achievement, Huluwa Xiao Er Fei Re Ke Chuan Granules had received multiple industry accolades, including the titles of “Proprietary Chinese Medicine Brand with Clinical Values” and “Most Cooperative Valuable Single Product of Chinese Chain Drugstores”. It was also honored with a place on the “China Pharmaceutical Brand List”.

Huluwa Pharmaceutical Group firmly upholds innovation as its primary driving force, placing great emphasis on scientific and technological advancements. It is also the first representative company in children's medicine and traditional Chinese medicine (TCM) from Hainan to join the China Association for Science and Technology. Looking ahead, the Huluwa Pharmaceutical remains committed to the guiding principle of “starting from practical needs”, as emphasized at the Hainan Provincial Science and Technology Award Conference. It adheres to three key innovation philosophies: “building a unique foundation to attract top talent”, “focusing on meaningful innovation rather than innovation for its own sake”, and “embracing openness to drive innovation”. Guided by its corporate mission, “Huluwa for Healthy Chinese Children”, the Huluwa Pharmaceutical will continue to enhance its scientific and technological innovation, drive high-quality development in pediatric pharmaceuticals, and support Hainan’s role as a key province in China’s national scientific and technological innovation system, contributing to the high-standard development of the Hainan Free Trade Port.